Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01958320 · ClinicalTrials.gov registry record · Phase 2

Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus

A Phase 2 study of Surgery and Necrotizing Enterocolitis, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 2
Development phase
202
Enrollment target
18
Study locations

NCT01958320 is a Phase 2 study of Surgery and Necrotizing Enterocolitis that has completed, run by University of California, San Francisco. The registered enrollment target is 202 participants, below the 52,850-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 18 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01958320, a Phase 2 study of Surgery and Necrotizing Enterocolitis, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 2
Development phase
202 participants
Enrollment target
18
Study locations

Study Summary

The primary goal of the trial is to compare two different Patent Ductus Arteriosus (PDA) treatment approaches: 1) an "early treatment" approach or 2) a "conservative" approach. For the purposes of the study infants will be enrolled if they are delivered before 28 weeks gestation and have a moderate/large PDA present at 5-7 days after birth. The hypothesis is: treatment of a moderate size patent ductus arteriosus (PDA) will decrease the time needed for assisted respiratory support, diuretic therapy, and gavage feeding assistance, in addition to decreasing the incidence of ductus ligations or need for future outpatient cardiology follow-up appointments. The investigators hypothesize that one or more of these benefits will occur without an increase in the time taken to achieve full enteral feedings or in the incidence of necrotizing enterocolitis (NEC) or spontaneous intestinal perforations (SIP).The investigators will be comparing the effectiveness of early pharmacologic treatment with a control group of conservatively managed infants who will only receive treatment if they meet specific criteria for "rescue treatment".

Interventions

  • DRUG NSAID
  • OTHER pharmacologic treatment of the PDA
  • OTHER no pharmacologic treatment of the PDA

Study Locations (18)

California

  • University of California San Diego - San Diego
  • Sharp Mary Birch Hospital for Women and Newborns - San Diego
  • University of California San Francisco - San Francisco
  • Mednax Neonatology of San Jose/Pediatrix Medical Group - San Jose
  • Kaiser Permanente Santa Clara - Santa Clara

Other

  • University Hospital, Umea, Sweden - Umeå
  • Ankara University School of Medicine Children's Hospital - Ankara
  • Sisli Hamidiye Etfal Training and Research Hospital - Istanbul
  • Inonu University School of Medicine Turgut Ozal Medical Center - Malatya

Illinois

  • University of Chicago Medicine - Chicago
  • Northshore University Health System - Evanston

Florida

  • South Miami Hospital - Miami

Maryland

  • Johns Hopkins University - Baltimore

Minnesota

  • Mayo Clinic - Rochester

New Jersey

  • Morristown Medical Center - Morristown

New York

  • Columbia University - New York

Trial Details

FieldValue
Enrollment Target 202 participants
Start Date 2013-12
Est. Completion 2017-06
Phase Phase 2

What the Registry Record Tells You About NCT01958320

The ClinicalTrials.gov registry entry for NCT01958320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52,850-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Surgery appearing as the primary indexed condition, and to 3 interventions - of which NSAID is the first listed.

NCT01958320 reports 18 study locations spanning 10 distinct geographic areas - top geographies include California, Other, Illinois.

Frequently Asked Questions

What is clinical trial NCT01958320 about?

NCT01958320 is a clinical study titled "Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus". The primary goal of the trial is to compare two different Patent Ductus Arteriosus (PDA) treatment approaches: 1) an "early treatment" approach or 2) a "conservative" approach. For the purposes of the study infants will be enrolled if they are delivered before 28 weeks gestation and have a moderate/...

What is the current status of trial NCT01958320?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2013-12. Estimated completion is 2017-06.

What conditions does trial NCT01958320 study?

This clinical trial studies the following conditions: Surgery, Necrotizing Enterocolitis, Patent Ductus Arteriosus, Intestinal Perforation.

What interventions are being tested in trial NCT01958320?

The interventions under investigation include: NSAID (DRUG), pharmacologic treatment of the PDA (OTHER), no pharmacologic treatment of the PDA (OTHER).

Who is sponsoring clinical trial NCT01958320?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01958320 being conducted?

This trial has 18 study locations across California, Florida, Illinois, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.